Bourhafour Mouna, Belbaraka Rhizlane, Souadka Amine, M'rabti Hind, Tijami Fouad, Errihani Hassan
Department of Medical Oncology, National Institute of Oncology, Rabat-10000, Morocco.
BMC Res Notes. 2011 Jun 29;4:219. doi: 10.1186/1756-0500-4-219.
Male breast cancer (MBC) is a rare disease representing less than 1% of all malignancies in men and only 1% of all incident breast cancers. Our study details clinico-pathological features, treatments and prognostic factors in a large Moroccan cohort.
One hundred and twenty-seven patients were collected from 1985 to 2007 at the National Institute of Oncology in Rabat, Morocco.Median age was 62 years and median time for consultation 28 months. The main clinical complaint was a mass beneath the areola in 93, 5% of the cases. Most patients have an advanced disease. Ninety-one percent of tumors were ductal carcinomas.Management consisted especially of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy with or without chemotherapy. The median of follow-up was 30 months. The evolution has been characterized by local recurrence; in twenty two cases (17% of all patients). Metastasis occurred in 41 cases (32% of all patients). The site of metastasis was the bone in twenty cases; lung in twelve cases; liver in seven case; liver and skin in one case and pleura and skin in one case.
Male breast cancer has many similarities to breast cancer in women, but there are distinct features that should be appreciated. Future research for better understanding of this disease at national or international level are needed to improve the management and prognosis of male patients.
男性乳腺癌(MBC)是一种罕见疾病,在所有男性恶性肿瘤中占比不到1%,在所有新发乳腺癌中仅占1%。我们的研究详细阐述了一个大型摩洛哥队列中的临床病理特征、治疗方法和预后因素。
1985年至2007年期间,在摩洛哥拉巴特的国家肿瘤研究所收集了127例患者。中位年龄为62岁,中位就诊时间为28个月。主要临床症状为乳晕下肿块,占93.5%的病例。大多数患者患有晚期疾病。91%的肿瘤为导管癌。治疗主要包括根治性乳房切除术;其次是辅助放疗和激素治疗,可联合或不联合化疗。中位随访时间为30个月。病情发展的特点是局部复发;22例(占所有患者的17%)。41例(占所有患者的32%)发生转移。转移部位为骨20例;肺12例;肝7例;肝和皮肤1例;胸膜和皮肤1例。
男性乳腺癌与女性乳腺癌有许多相似之处,但也有一些独特的特征需要认识到。需要在国家或国际层面开展进一步研究以更好地了解这种疾病,从而改善男性患者的治疗和预后。